{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:16:59Z","timestamp":1747196219180,"version":"3.40.5"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH IeDEA","award":["U01AI069907"],"award-info":[{"award-number":["U01AI069907"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The use of holding regimens for people living with HIV (PLWH) without effective antiretroviral options can have effects on outcomes and future treatment options. We aimed to investigate the use of holding regimens for PLWH in Asian countries. Data from adults enrolled in routine HIV care in IeDEA Asia-Pacific cohorts were included. Individuals were considered to be on holding regimen if they had been on combination antiretroviral therapy for at least 6 months, had two confirmed viral loads (VL) \u22651000 copies\/mL, and had remained on the same medications for at least 6 months. Survival time was analyzed using Fine and Gray\u2019s competing risk regression. Factors associated with CD4 changes and VL &lt;1000 copies\/mL were analyzed using linear regression and logistic regression, respectively. A total of 425 PLWH (72.9% male; 45.2% high-income and 54.8% low-to-middle-income country) met criteria for being on a holding regimen. From high-income countries, 63.0% were on protease inhibitors (PIs); from low-to-middle-income countries, 58.4% were on non-nucleoside reverse transcriptase inhibitors (NNRTIs); overall, 4.5% were on integrase inhibitors. The combination of lamivudine, zidovudine, and efavirenz was the most commonly used single regimen (n = 46, 10.8%), followed by lamivudine, zidovudine, and nevirapine (n = 37, 8.7%). Forty-one PLWH (9.7%) died during follow-up (mortality rate 2.0 per 100 person-years). Age &gt;50 years compared to age 31\u201340 years (sub-hazard ratio [SHR] 3.29, 95% CI 1.45\u20137.43, p = 0.004), and VL \u22651000 copies\/ml compared to VL &lt;1000 copies\/mL (SHR, 2.14, 95% CI 1.08\u20134.25, p = 0.029) were associated with increased mortality, while higher CD4 counts were protective. In our Asia regional cohort, there was a diversity of holding regimens, and the patterns of PI vs. NNRTI use differed by country income levels. Considering the high mortality rate of PLWH with holding regimen, efforts to extend accessibility to additional antiretroviral options are needed in our region.<\/jats:p>","DOI":"10.1371\/journal.pone.0264157","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T17:34:26Z","timestamp":1648661666000},"page":"e0264157","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patterns and prognosis of holding regimens for people living with HIV in Asian countries"],"prefix":"10.1371","volume":"17","author":[{"given":"Jung Ho","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awachana","family":"Jiamsakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasisopin","family":"Kiertiburanakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bui Vu","family":"Huy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suwimon","family":"Khusuwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagalingeswaran","family":"Kumarasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oon Tek","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penh Sun","family":"Ly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man-Po","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Jiun","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmin Mohamed","family":"Gani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iskandar","family":"Azwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anchalee","family":"Avihingsanon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuti Parwati","family":"Merati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Pujari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1241-5954","authenticated-orcid":true,"given":"Romanee","family":"Chaiwarith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fujie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Tanuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuong Duy","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Ditangco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evy","family":"Yunihastuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2775-3315","authenticated-orcid":true,"given":"Jun Yong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of IeDEA Asia-Pacific","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"key":"pone.0264157.ref001","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","article-title":"Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies","volume":"360","author":"M Egger","year":"2002","journal-title":"Lancet"},{"key":"pone.0264157.ref002","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"RT Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"pone.0264157.ref003","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1468-1293.2011.00953.x","article-title":"Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials","volume":"13","author":"M Pichenot","year":"2012","journal-title":"HIV Med"},{"issue":"Suppl 3","key":"pone.0264157.ref004","doi-asserted-by":"crossref","first-page":"S474","DOI":"10.1086\/521116","article-title":"Challenges to pediatric HIV care and treatment in South Africa","volume":"196","author":"T Meyers","year":"2007","journal-title":"J Infect Dis"},{"key":"pone.0264157.ref005","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection","volume":"359","author":"DA Cooper","year":"2008","journal-title":"N Engl J Med"},{"key":"pone.0264157.ref006","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/QAI.0b013e3181c42ea4","article-title":"Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy","volume":"54","author":"H Hatano","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0264157.ref007","first-page":"23","article-title":"Management of HIV infection after triple class failure","volume":"36","author":"F Cossarini","year":"2013","journal-title":"New Microbiol"},{"key":"pone.0264157.ref008","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3947\/ic.2019.51.1.77","article-title":"The 2018 Clinical Guidelines for the Diagnosis and Treatment of HIV\/AIDS in HIV-Infected Koreans","volume":"51","year":"2019","journal-title":"Infect Chemother"},{"key":"pone.0264157.ref009","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(04)16589-6","article-title":"Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes","volume":"364","author":"B Ledergerber","year":"2004","journal-title":"Lancet"},{"key":"pone.0264157.ref010","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/01.qai.0000136738.24090.d0","article-title":"Effect of persistent moderate viremia on disease progression during HIV therapy","volume":"37","author":"SP Raffanti","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0264157.ref011","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1097\/01.aids.0000131358.29586.6b","article-title":"Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy","volume":"18","author":"R Kantor","year":"2004","journal-title":"Aids"},{"key":"pone.0264157.ref012","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/01.qai.0000245882.28391.0c","article-title":"Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure","volume":"43","author":"MB Goetz","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0264157.ref013","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials","volume":"369","author":"B Clotet","year":"2007","journal-title":"Lancet"},{"key":"pone.0264157.ref014","doi-asserted-by":"crossref","first-page":"e0154221","DOI":"10.1371\/journal.pone.0154221","article-title":"Role of rilpivirine and etravirine in efavirenz and nevirapine-based regimens failure in a resource-limited country: a cross-sectional study","volume":"11","author":"P Teeranaipong","year":"2016","journal-title":"PloS one"},{"key":"pone.0264157.ref015","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/01.qai.0000145351.96815.d5","article-title":"The TREAT Asia HIV Observational Database: baseline and retrospective data","volume":"38","author":"J Zhou","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0264157.ref016","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3851\/IMP3041","article-title":"Improved survival in HIV treatment programmes in Asia","volume":"21","author":"NL De La Mata","year":"2016","journal-title":"Antivir Ther"},{"key":"pone.0264157.ref017","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1177\/0956462417699538","article-title":"Trends in CD4 cell count response to first-line antiretroviral treatment in HIV-positive patients from Asia, 2003\u20132013: TREAT Asia HIV Observational Database Low Intensity Transfer","volume":"28","author":"NL De La Mata","year":"2017","journal-title":"Int J STD AIDS"},{"volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach","year":"2016","author":"Organization WH","key":"pone.0264157.ref018"},{"journal-title":"Countries and Economies","year":"2015","author":"The World Bank","key":"pone.0264157.ref019"},{"key":"pone.0264157.ref020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12981-015-0053-z","article-title":"Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand","volume":"12","author":"W Manosuthi","year":"2015","journal-title":"AIDS Res Ther"},{"key":"pone.0264157.ref021","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3947\/ic.2013.45.4.455","article-title":"The 2013 Clinical Guidelines for the Diagnosis and Treatment of HIV\/AIDS in HIV-Infected Koreans","volume":"45","year":"2013","journal-title":"Infect Chemother"},{"key":"pone.0264157.ref022","doi-asserted-by":"crossref","first-page":"e1001907","DOI":"10.1371\/journal.pmed.1001907","article-title":"The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020","volume":"12","author":"A Dutta","year":"2015","journal-title":"PLoS Med"},{"key":"pone.0264157.ref023","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/cid\/ciy763","article-title":"Safety, Tolerability, and Efficacy of Generic Dolutegravir-containing Antiretroviral Therapy Regimens Among South Indian Human Immunodeficiency Virus-infected Patients","volume":"68","author":"N Kumarasamy","year":"2019","journal-title":"Clin Infect Dis"},{"key":"pone.0264157.ref024","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1097\/QAD.0000000000001845","article-title":"The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?","volume":"32","author":"M Vitoria","year":"2018","journal-title":"Aids"},{"key":"pone.0264157.ref025","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.1016\/S2352-3018(18)30093-6","article-title":"Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research","volume":"5","author":"J Dorward","year":"2018","journal-title":"Lancet HIV"},{"key":"pone.0264157.ref026","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(18)30710-2","article-title":"Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens","volume":"19","author":"SC Inzaule","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"pone.0264157.ref027","doi-asserted-by":"crossref","first-page":"e25219","DOI":"10.1002\/jia2.25219","article-title":"Trends in mortality among ART-treated HIV-infected adults in the Asia-Pacific region between 1999 and 2017: results from the TREAT Asia HIV Observational Database (TAHOD) and Australian HIV Observational Database (AHOD) of IeDEA Asia-Pacific","volume":"22","author":"IY Jung","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"pone.0264157.ref028","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/aje\/kwaa049","article-title":"The Impact of Delayed Switch to Second-Line Antiretroviral Therapy on Mortality, Depending on Definition of Failure Time and CD4 Count at Failure","volume":"189","author":"H Bell-Gorrod","year":"2020","journal-title":"Am J Epidemiol"},{"key":"pone.0264157.ref029","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/QAI.0000000000002313","article-title":"Increased Mortality With Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South Africa","volume":"84","author":"H Bell Gorrod","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0264157.ref030","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/QAD.0b013e32833a0918","article-title":"Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study","volume":"24","author":"C Smith","year":"2010","journal-title":"Aids"},{"key":"pone.0264157.ref031","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/QAI.0b013e3181b79d22","article-title":"Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era","volume":"53","author":"L Cockerham","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0264157.ref032","doi-asserted-by":"crossref","first-page":"e0205455","DOI":"10.1371\/journal.pone.0205455","article-title":"Lamivudine monotherapy as a holding regimen for HIV-positive children","volume":"13","author":"G Patten","year":"2018","journal-title":"PLoS One"},{"key":"pone.0264157.ref033","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jadohealth.2019.07.025","article-title":"Peritransition Outcomes of Southeast Asian Adolescents and Young Adults With HIV Transferring From Pediatric to Adult Care","volume":"66","author":"AH Sohn","year":"2020","journal-title":"Journal of Adolescent Health"},{"key":"pone.0264157.ref034","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1468-1293.2009.00738.x","article-title":"Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD)","volume":"11","author":"J Zhou","year":"2010","journal-title":"HIV medicine"},{"key":"pone.0264157.ref035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/QAI.0000000000000108","article-title":"Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV1-infected patients in South East Asia","volume":"66","author":"P Phanuphak","year":"2014","journal-title":"Journal of acquired immune deficiency syndromes (1999)"},{"key":"pone.0264157.ref036","doi-asserted-by":"crossref","first-page":"19053","DOI":"10.7448\/IAS.17.1.19053","article-title":"HIV multi\u2010drug resistance at first\u2010line antiretroviral failure and subsequent virological response in Asia","volume":"17","author":"A Jiamsakul","year":"2014","journal-title":"Journal of the International AIDS Society"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0264157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T12:29:05Z","timestamp":1700396945000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0264157"}},"subtitle":[],"editor":[{"given":"Carlo","family":"Torti","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0264157","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,3,30]]}}}